Drug Trial Radar · NCT04848506
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
900
Planned (sponsor's estimate)
Start
May 6, 2021
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- CytokineticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
Conditions
- Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)Drug
Aficamten tablets, 5-20 mg daily, administered orally. Participants may continue on Aficamten until end of treatment criteria defined in the protocol is met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events observed during dosing of aficamten in patients with HCMTime frame: Baseline to End of study, up to 5 years
- Incidence of serious adverse events observed during dosing of aficamten in patients with HCMTime frame: Baseline to End of study, up to 5 years
- Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of aficamten in patients with HCMTime frame: Baseline to End of study, up to 5 years
Locations
141 sites in 19 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Alaska Heart and Vascular Institute
Anchorage, Alaska
Mayo Clinic Building - Phoenix
Phoenix, Arizona
UC San Diego Health - Sulpizio Cardiovascular Center
La Jolla, California
Cedar-Sinai Medical Center
Los Angeles, California
Cedars-Sinai Medical Center (Smidt Heart Institute)
Los Angeles, California
UCLA Health System - UCLA Cardiovascular Center
Los Angeles, California
UCSF Medical Center
San Francisco, California
Yale New Haven Hospital
New Haven, Connecticut
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Holy Cross Hospital / Cardiology Associates
Fort Lauderdale, Florida
Emory Clinic
Atlanta, Georgia
Piedmont Fayette Hospital
Fayetteville, Georgia
The Queen's Medical Center
Honolulu, Hawaii
Northwestern University
Chicago, Illinois
The University of Iowa Hospitals & Clinics
Iowa City, Iowa
The University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Lahey Hospital & Medical Center
Burlington, Massachusetts
Michigan Medicine - University of Michigan
Ann Arbor, Michigan
University of Michigan Health System (UMHS) - University Hospital (University of Michigan Medical Center)
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Saint Luke's Hospital of Kansas City
Kansas City, Missouri
Morristown Medical Center
Morristown, New Jersey
Northwell Health North Shore University Hospital
Manhasset, New York
NYU Langone Health
New York, New York
Weill Cornell Medicine
New York, New York
Mount Sinai Hospital
New York, New York
Columbia University Medical Center/New York Presbyterian Hospital
New York, New York
Westchester Medical Center
Valhalla, New York
Sanger Heart & Vascular Institute, Atrium Health
Charlotte, North Carolina
Duke Cardiology at Southpoint
Durham, North Carolina
The Linder Research Center at The Christ Hospital
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Ascension St. John Clinical Research Institute
Tulsa, Oklahoma
Providence St. Vincent Medical Center
Portland, Oregon
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.